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Introduction
Hashimoto’s encephalopathy (HE) is a controversial and 
poorly understood encephalopathy of  presumed autoim-
mune origin. It was initially described by Lord Brain in 
1966 (1), and its name reflects the association with Hashi-
moto’s thyroiditis. Since this neurological disorder also ap-
pears to be associated with other autoimmune thyroid dis-
eases, such as Grave´s diseases (2), the name “encephalopa-
thy associated with autoimmune thyroid diseases” seems 
more appropriate. Although Brain’s original patient did not 
improve with corticosteroid treatment, most patients who 
were later described did improve. This led to the renaming 
of  HE by some as “steroid-responsive encephalopathy asso-
ciated with autoimmune thyroiditis” (SREAT) (3). The 
pathogenesis of  HE is unknown; however, some evidence of 
a nonvasculitic process has been reported that supports the 
term “nonvasculitic autoimmune inflammatory menin-
goencephalitis” (NAIM) as another denomination of  
HE (4). 
HE is characterized by an association of  symptoms of  
acute or subacute encephalopathy with high levels of  anti-
thyroid antibodies, often without clinical or biochemical 
evidence of  thyroid dysfunction (5, 6). Neurological mani-
festations are heterogeneous, but two main types are usually 
seen: strokelike episodes with focal and transient neurologi-
cal deficits, or a progressive cognitive decline leading to 
dementia or psychosis (7). Seizures may coexist in both 
types, and manifestations may overlap in the same patient. 
Accurate and prompt diagnosis is important, because ap-
propriate treatment is almost always successful and perma-
nent impairment can result if  the condition is left 
untreated. 
Case report
A 37-year-old Caucasian female presented with symp-
toms of  depression of  6 months' duration. She was diag-
nosed with hypothyroidism and treated, but experienced no 
improvement. Antidepressant therapy was started, also 
without improvement. She was referred to our institution 
because of  progressive short- and long-term memory loss 
and sleepiness. During the course of  the disease, she re-
ported approximately a 20-kg weight loss. She had previ-
ously been working but was now on short-term disability. 
On physical examination, she was alert and oriented. Her 
short-term memory was impaired, but long-term memory 
was judged to be intact. Attention and concentration were 
adequate. Neurological examination was otherwise normal. 
Routine laboratory tests (full blood count, hemoglobin, 
erythrocyte sedimentation rate, platelets, creatinine, blood-
urea nitrogen, glucose, transaminases, and proteins) were 
normal. Thyroid-stimulating hormone (TSH) values were 
within normal limits. Infectious serologies were negative, 
including those of  Lyme disease, Rocky Mountain spotted 
fever, syphilis, HIV, and hepatitis A, B, and C. Serum cop-
per, vitamin B12, and angiotensin-converting enzyme 
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(ACE) levels were also normal. Total antinuclear antibodies  
(ANA), antineutrophil cytoplasmic antibodies (pANCA), 
double-stranded DNA (anti-dsDNA) antibodies, and antiri-
bonucleoprotein (anti-RNP) antibodies were positive, while 
anti-Sjogren (anti-SSA, anti-SSB), anti-Scl-70, antichroma-
tin antibodies, and rheumatoid factor were negative.
A lumbar puncture revealed 82 total nucleated cells, 99% 
lymphocytes, protein 84 mg/dl (15-45mg/dl), and glucose 
62mg/dl (50-75mg/dl). CSF was tested for multiple atypi-
cal CNS infections, all of  which proved to be negative. This 
included herpes simplex virus (HSV) polymerase chain 
reaction (PCR), variella zoster virus (VZV) PCR, cy-
tomegalovirus (CMV) PCR, human herpes virus 6 (HHV-
6) PCR, and Epstein-Barr virus (EBV) PCR. Venereal dis-
ease research laboratory test (VDRL) and cryptococcal 
antigen were also negative. A CSF culture and arbovirus 
panel including eastern equine, western equine, St. Louis, 
LaCrosse, and west Nile were all negative. Angiotensin-
converting enzyme (ACE) was negative. CSF oligoclonal 
bands revealed 1 to 3 bands unique to the CSF. The immu-
noglobulin G (IgG)-CSF index was within the normal lim-
its. A CSF paraneoplastic panel including collapsin re-
sponse mediator protein-5 (CRMP-5), IgG, amphiphysin 
antibody, Purkinje cell cytoplasmic antibody (PCA) trotter 
antigen (TR), PCA-2, PCA-1, antiglial nuclear antibody 
(AGNA)-1, antineuronal nuclear antibody (ANNA)-3, 
ANNA-2, and ANNA-1 all returned negative. Voltage-
gated potassium channel and NMDA (N-methyl D-
aspartate) antibodies were also negative. 
The possibility of  Hashimoto’s encephalitis was consid-
ered, and an antithyroid antibody test was requested. Anti-
thyroglobulin (anti-TG) antibodies were greater than 500 
IU/mL (normal < 4 IU/mL), and antithyroid peroxidase 
(anti-TPO) antibodies were 343.4 IU/mL 
(normal < 4 IU/mL). 
Brain MRI revealed symmetric and bilateral areas of  
abnormally high signal on T2-weighted and fluid-
attenuated inversion recovery (FLAIR) images involving the 
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Figure 1. 37-year-old female with Hashimoto's encephalopathy. Brain MRI performed six months after the onset of symptoms. 
Axial T2 (A and B) and axial FLAIR (C and D) show symmetric and bilateral areas of abnormal high signal on T2-weighted and 
fluid attenuation inversion recovery (FLAIR) images involving the mesial temporal lobes, caudate nuclei, and putamina (black 
arrows). The basal ganglia lesions are minimally hyperintense on T1-weighted images (E). These lesions have fine serpigi-
nous enhancement on T1-weighted postcontrast images (G and H) (white arrows). Additionally, a left midbrain lesion, hyperin-
tense on T2-weighted and FLAIR images (A and C),shows no enhancement after gadolinium administration (F) (small arrows).
mesial temporal lobes, caudate nuclei, and putamina. 
These lesions were slightly hyperintense on T1-weighted 
images, with fine serpiginous enhancement after gadolin-
ium administration. Additionally, a left midbrain lesion, 
hyperintense on T2-weighted and FLAIR images, was seen. 
This lesion had no enhancement after gadolinium admini-
stration. No hemorrhage or mass effect was seen. No 
diffusion-weighted signal abnormality was identified (Fig. 
1). MR angiograms of  the circle of  Willis and neck were 
normal. To exclude possible paraneoplastic limbic en-
cephalitis, abdomen and pelvis CT scans were obtained 
and were normal. 
Clinical history and laboratory findings were deemed 
consistent with HE, and the patient started prednisone (60 
mg daily). A six-month followup brain MRI showed some 
improvement, with reduction in the extent of  the high T2 
signal lesions in the mesial temporal lobes, basal ganglia, 
and midbrain, and resolution of  the gadolinium enhance-
ment. The high T1 precontrast signal in the basal ganglia 
present in the previous exam was more evident (Fig. 2). At 
this point, thyroglobulin antibody had decreased to 141IU/
mL (normal < 4 IU/mL), and thyroid peroxidase antibody 
was 23IU/mL (normal < 4 IU/mL). 
Discussion
HE is an extremely rare condition associated with auto-
immune thyroid diseases. Since Brain’s first description in 
1966 (1), approximately 200 new cases have been reported 
in the literature, but few with associated MRI. The preva-
lence has been estimated to be 2.1/100,000 (4), but some 
benign forms may still be undiagnosed (7).
Hashimoto’s encephalopathy, like autoimmune thyroid 
disease, is more common in women than in men and has 
been reported in pediatric, adult, and elderly populations 
throughout the world (4). 
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Figure 2. 37-year-old female with Hashimoto's encephalopathy. Six-month followup brain MRI. Axial T2 (A and B), axial FLAIR 
(C and D), axial T1 (E), and axial T1-weighted postcontrast (F, G, and H) weighted images show some improvement with re-
duction in the extent of the high T2/FLAIR signal lesions in the mesial temporal lobes and basal ganglia, with resolution of 
gadolinium enhancement. The high T1 precontrast signal in the basal ganglia is now much more evident (E). The left midbrain 
lesion present in the previous exam is currently not seen.
The clinical features of  Hashimoto’s encephalopathy can 
be quite varied. By definition, patients present with en-
cephalopathy (100%). This nonspecific alteration of  mental 
state is characterized by abnormal consciousness, impaired 
attention and cognition, and associated changes in behavior 
and personality. Although no particular pattern of  cogni-
tive dysfunction is specified, memory dysfunction is com-
mon. Seizures (66%), myoclonus (38%), neuropsychiatric 
symptoms (36%), and strokelike symptoms (27%) are also 
seen (6, 8). EEG findings are nonspecific. The most fre-
quently reported abnormality is a slow wave background, 
associated with any encephalopathic process, often reflect-
ing the severity of  the clinical picture (4).
Diagnosis is made in the first instance by excluding other 
toxic, metabolic, inflammatory, ischemic, and infectious 
causes of  encephalopathy as well as primary degenerative 
CNS diseases, as was done with our patient. Common dif-
ferential diagnoses are Creutzfeldt-Jakob disease, other rap-
idly progressive dementias, central nervous system vasculi-
tis, paraneoplastic and nonparaneoplastic limbic encephali-
tis, and primary psychiatric diseases. 
In most cases of  HE, routine blood investigations are 
normal. Nonspecific findings of  inflammation, such as mild 
elevations of  erythrocyte sedimentation rate, C-reactive 
protein, or liver aminotransferase levels have been reported.  
As with our patient, antibody markers of  autoimmune dis-
eases can also be detected. These investigations are often 
not helpful in the diagnosis of  HE because they are also 
common and similar to other forms of  autoimmune en-
cephalopathy (6). Thyroid hormone studies are also not 
helpful, but they may identify subclinical thyroid 
dysfunction. 
The diagnosis of  HE is based on the detection of  anti-
thyroid antibodies, particularly antithyroid peroxidase (anti-
TPO) antibody (also referred to as antimicrosomal anti-
body) and antithyroglobulin (anti-TG) antibodies. Antithy-
roid antibodies are present in 5% to 20% of  the general 
population, and this percentage normally increases with 
age and female gender (4, 6). For that reason, high titers 
(usually 100-fold over normal), as found in our patient, are 
necessary for the diagnosis of  HE. The pathogenic role of  
these antibodies is still debated. They can also be detected 
in paraneoplastic and nonparaneoplastic limbic encephali-
tis, as well as in other autoimmune disorders, suggesting 
that the antibodies are markers of  autoimmune encephalitis 
rather than directly involved in the pathogenesis of  HE. 
With our patient, the main differential diagnosis was limbic 
encephalitis, but specific serum antineuronal antibodies 
found in paraneoplastic and nonparaneoplastic limbic en-
cephalitis were negative, as was a body CT scan.
Another controversial issue is whether the titer of  anti-
bodies correlates with the stage of  the disease. Some studies 
describe a reduction of  antibodies after remittance of  
symptoms, either spontaneously or induced by therapy as 
with our patient, while others describe the opposite (9).
Thyroid antibodies are also detected in paraneoplastic 
and nonparaneoplastic limbic encephalitis, as well as in a 
number of  other autoimmune disorders. This suggests that 
antithyroid antibodies may be bystanders rather than hav-
ing a direct role (4). In HE, elevated CSF proteins are 
found in 80% of  patients, and a mild lymphocytic pleocyto-
sis in 20% to 80% (4). These findings were also present in 
our patient. Ferraci at al (5) indentified antithyroid antibod-
ies and circulating immune complexes in the CSF of  six 
patients with HE. The data were consistent with the integ-
rity of  the blood-brain barrier (BBB) and intrathecal syn-
thesis of  auto-antibodies. The authors believe that this CSF 
finding may be useful in the diagnosis of  HE in all patients 
with unexplained acute or subacute encephalopathy (5). In 
our case, CSF antithyroid antibody was not tested. Never-
theless, antithyroid antibodies are not always detected in 
CSF. 
MRI is normal in approximately 50% of  patients with 
HE. In the remaining patients, the most common findings 
reported are generalized cerebral atrophy, diffuse increased 
signal on T2-weighted and FLAIR images in subcortical 
white matter, and dural enhancement. Cerebellar T2 
hyperintense lesions or atrophy are rarely seen (4, 10). With 
our patient, the location of  the abnormalities, predomi-
nantly the mesial temporal lobes and basal ganglia, was 
unusual. Severe amnesic syndrome with similar bilateral 
mesial temporal lobe involvement has been reported in two 
cases (11, 12). However, as far as we know, bilateral basal 
ganglia involvement has not been previously described. 
These MRI findings illustrate the wide range of  MRI ap-
pearances that can be seen in Hashimoto’s encephalopathy 
and the fact that strong suspicion and adequate laboratory 
findings are essential in making the diagnosis. Some of  the 
brain MRI changes may resolve with treatment (6). With 
our patient, some improvement was seen, but a number of  
MRI lesions persisted despite steroid therapy. 
Diffusion-weighted MR imaging (DWI) in one HE pa-
tient showed restricted diffusion that resolved after therapy. 
The authors underlined the importance of  including DWI 
in the evaluation of  these patients not only to assess the 
possibility of  vasculitis but also to provide a measure of  
response to treatment (8). MR spectroscopy in a patient 
with HE demonstrated reduction of  N-acetyl-aspartate 
(NAA) and increased choline (Cho), which returned to 
normal after treatment. Since NAA and Cho are markers 
of  the integrity of  neurons and the myelin sheath, respec-
tively, these data suggest a transient condition involving 
both neurons and oligodendrocytes (9). Single photon-
emission computed tomography (SPECT) has demon-
strated nonspecific patterns of  reduced blood flow involving 
multiple regions in some patients with HE (4). Positron-
emission tomography (PET) scans have shown some non-
specific hypometabolism (9). SPECT and PET did not cor-
relate with EEG or neuroradiologic findings (9).
Different approaches to treatment have been recom-
mended. A short course of  high-dose intravenous corticos-
teroids or oral prednisone is the typical initial therapy. Most 
patients show a response to treatment within weeks, and 
some show a dramatic improvement after the first few 
doses. Discontinuation of  treatment can be considered in 
patients who remain stable a year or more (6). Some cases 
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of  HE are refractory or only partially responsive to corti-
costeroids. There is some evidence that azathioprine may 
be helpful, usually when combined with corticosteroids. 
Intravenous immune globulin and plasma exchange may 
also be effective as an initial treatment or when corticoster-
oids are not efficacious. Other treatments include cyclo-
phosphamide and methotrexate, with variable degrees of  
success (4).
Conclusion
The term HE is loosely applied to a variety of  encepha-
lopathic patients who have elevated titers of  antithyroid 
antibodies with various clinical presentations, neuroimaging 
findings, thyroid hormone levels, and cerebrospinal fluid 
findings. Its pathogenesis remains unclear, but good clinical 
response to corticosteroids and presence of  elevated serum 
levels of  antithyroid antibodies suggest an autoimmune 
pathogenesis. 
Brain MRI is frequently normal. When it is abnormal, a 
wide range of  MRI appearances may be seen. The most 
typical findings are generalized cerebral atrophy and 
changes in subcortical white matter and meninges. How-
ever, radiologists should be aware that atypical MRI find-
ings as described here may be present. As far as we know, 
bilateral basal ganglia involvement has not been previously 
described.
Despite the suggestive laboratory and neuroimaging find-
ings, at this time, Hashimoto’s encephalopathy is still a di-
agnosis of  exclusion based on elevation of  serum antithy-
roid antibodies in the appropriate clinical context.
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